Publication | Closed Access
An open-label, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): POLLUX
13
Citations
0
References
2016
Year
Hematological MalignancyMedicineRandomised Phase 3ImmunologyPathologyImmune Checkpoint InhibitorVersus LenalidomideImmunotherapyOncologyRadiation OncologyRefractory Multiple Myeloma
No additional data available for this publication yet. Check back later!